secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2026-05-12T11:01:41+00:00
Accession:  0001628280-26-033856
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics Q1 net loss $65.5M; cash $60M; enters $35M Oberland debt facility
-------------------------------------------------------------------------------

- Net loss $65.5M ($0.75 per share) vs $8.2M loss a year ago; includes non-cash warrant liability fair value change.
- Revenue $2.2M from Viatris collaboration, down from $4.4M.
- Cash $60M at March 31; post-quarter $35M senior secured notes from Oberland Capital plus $5M equity; total ~$90M funds into 2029.
- LCA5 program accepted into FDA's RDEP program; pivotal Phase 3 enrollment ongoing, dosing expected Q4 2026.
- BEST1 Cohort 1 topline data expected September 2026; R&D Science Forum June 16.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/0001628280-26-033856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000162828026033856/ird-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-033856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer